Protalix BioTherapeutics, Inc. (PLX) 株式分析

企業概要

Protalix BioTherapeutics, Inc. is a biopharmaceutical entity engaged in the development, production, and commercialization of recombinant therapeutic proteins derived from its proprietary ProCellEx plant cell-based protein expression system. This enterprise operates within the Healthcare sector, specifically targeting the Biotechnology industry, where it leverages biological mechanisms to manufacture pharmaceutical agents for therapeutic applications. The company's current financial scale is defined by a market capitalization of $172.42M and an annual revenue of $52.74M, supported by a workforce of 226 employees. These valuation and revenue figures indicate that the company holds a mid-cap profile, suggesting it is an established yet still developing player with significant cash reserves relative to its size, operating under the constraints typical of a biotechnology firm focused on specialized therapeutic proteins.

財務健全性

The company reported a revenue of $52.74M over the trailing twelve months, while posting a net income loss of $-6,604,000 and an EBITDA of $-4,035,000, revealing a substantial gap between top-line generation and bottom-line profitability that highlights a cost structure dominated by research, development, and operational expenses. Free cash flow stands at $-12,196,875, indicating that the company is currently burning cash to fund its operations and pipeline, which limits immediate financial flexibility but is often necessary for pre-commercialization or early-stage commercial biotechnology companies. Profitability metrics further illustrate this challenge, with a gross margin of 13.0%, an operating margin of -51.1%, and a profit margin of -12.5%, where the negative operating and profit margins reflect high overhead costs relative to sales volume and a lack of net income generation. Regarding solvency, the company holds $30.27M in cash against $8.32M in debt, resulting in a debt-to-equity ratio of 17.25, which suggests a leveraged balance sheet structure despite the low absolute debt amount, as the equity base is small. Short-term liquidity is robust, evidenced by a current ratio of 2.51, meaning the company possesses 2.51 times the assets required to cover its current liabilities without immediate distress. Return on equity is recorded at -14.4% and return on assets at -4.4%, metrics that reveal management is currently not generating positive returns on the capital deployed or the asset base utilized, consistent with the financial losses reported in the net income and EBITDA figures.

バリュエーション評価

Valuation multiples for Protalix BioTherapeutics, Inc. present a mixed picture of profitability and market pricing, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of 3.45, implying that the market is pricing in a significant anticipated improvement in earnings trajectory to justify current share prices. The price-to-book ratio stands at 3.57, indicating that the stock trades at a significant premium over its book value, a common characteristic for biotechnology firms where intangible assets and future pipeline potential are valued higher than historical book capital. Alternative valuation metrics such as a price-to-sales ratio of 3.27 and an EV/EBITDA of -37.29 suggest that investors are valuing the company primarily on revenue generation and market share potential rather than current cash flow or earnings, as the negative EV/EBITDA confirms the company's current unprofitability. Price momentum is captured by a 52-week high of $3.19 and a low of $1.32, placing the current trading price significantly below the yearly peak and reflecting the volatility often seen in small-cap biotech stocks. The beta value of -0.23 is highly anomalous for equities, suggesting an inverse correlation to the broader market or a data anomaly that implies price movements may not follow standard market trends, potentially offering a unique risk profile relative to the broader market index.

Growth & Income

Growth dynamics for the company are characterized by a revenue growth rate of -49.9% year-over-year and earnings growth of N/A, indicating that the company is currently shrinking in terms of top-line sales and has not achieved profitability to report meaningful earnings growth. The divergence between shrinking revenue and negative earnings growth implies that declining sales are exacerbating the company's cash burn rate, as fixed costs remain high while revenue contracts. As a non-dividend payer, the company does not distribute a dividend yield, which remains N/A, nor does it maintain a payout ratio, as the 0.0% figure reflects the retention of all available cash to fund operations and potentially invest in growth initiatives rather than shareholder distributions. Consequently, the overall growth and income profile is defined by a contractionary revenue trend and a complete absence of dividend income, forcing the company to rely entirely on external financing or internal cash reserves to sustain its development and commercialization efforts without distributing returns to shareholders.